SL Science Holding Limited is a dynamic company focused on leveraging advanced technologies to drive innovation in the scientific and healthcare sectors. With a commitment to developing cutting-edge solutions, SLBT is positioned to capitalize on emerging market trends and address critical challenges in biotechnology and life sciences. The company's strategic vision emphasizes research and development, fostering partnerships to enhance its product portfolio and expand its market presence. As an emerging player in this rapidly evolving industry, SLBT aims to deliver substantial long-term value for its stakeholders through sustainable growth and innovation.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | 1047.17 |
| Price-to-Sales (TTM) | 1088.47 |
| EV/Revenue | 1087.99 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $560.76M |
| Float | 0 |
| % Insiders | 59.55% |
| % Institutions | 0.39% |
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLBT and any ticker you trade — then tracks every position and per-strategy win rate.
